Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

MGST1, a GSH transferase/peroxidase essential for development and hematopoietic stem cell differentiation.

Bräutigam L, Zhang J, Dreij K, Spahiu L, Holmgren A, Abe H, Tew KD, Townsend DM, Kelner MJ, Morgenstern R, Johansson K.

Redox Biol. 2018 Jul;17:171-179. doi: 10.1016/j.redox.2018.04.013. Epub 2018 Apr 16.

2.

Hydroxyurea derivatives of irofulven with improved antitumor efficacy.

Staake MD, Kashinatham A, McMorris TC, Estes LA, Kelner MJ.

Bioorg Med Chem Lett. 2016 Apr 1;26(7):1836-8. doi: 10.1016/j.bmcl.2016.02.028. Epub 2016 Feb 13.

PMID:
26922141
3.

Absence of MGST1 mRNA and protein expression in human neuroblastoma cell lines and primary tissue.

Kelner MJ, Diccianni MB, Yu AL, Rutherford MR, Estes LA, Morgenstern R.

Free Radic Biol Med. 2014 Apr;69:167-71. doi: 10.1016/j.freeradbiomed.2014.01.021. Epub 2014 Jan 29.

4.

Structure-activity studies of urea, carbamate, and sulfonamide derivatives of acylfulvene.

McMorris TC, Chimmani R, Alisala K, Staake MD, Banda G, Kelner MJ.

J Med Chem. 2010 Feb 11;53(3):1109-16. doi: 10.1021/jm901384s.

PMID:
20067264
5.

Stability of levothyroxine sodium 0.4 microg/mL in 0.9% sodium chloride injection.

Stadalman KA, Kelner MJ, Box K, Dominguez A, Rigby JF.

Prog Transplant. 2009 Dec;19(4):354-6; quiz 357.

PMID:
20050459
6.

Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model.

Kelner MJ, McMorris TC, Rojas RJ, Estes LA, Suthipinijtham P.

Cancer Chemother Pharmacol. 2008 Dec;63(1):19-26. doi: 10.1007/s00280-008-0703-0. Epub 2008 Feb 28.

PMID:
18305940
7.

Synergy of Irofulven in combination with various anti-metabolites, enzyme inhibitors, and miscellaneous agents in MV522 lung carcinoma cells: marked interaction with gemcitabine and 5-fluorouracil.

Kelner MJ, McMorris TC, Rojas RJ, Estes LA, Suthipinijtham P.

Invest New Drugs. 2008 Oct;26(5):407-15. doi: 10.1007/s10637-008-9113-8. Epub 2008 Jan 29.

PMID:
18227973
8.

Disruption of the ugt1 locus in mice resembles human Crigler-Najjar type I disease.

Nguyen N, Bonzo JA, Chen S, Chouinard S, Kelner MJ, Hardiman G, Bélanger A, Tukey RH.

J Biol Chem. 2008 Mar 21;283(12):7901-11. doi: 10.1074/jbc.M709244200. Epub 2008 Jan 7.

9.

Synthesis and antitumor activity of amine analogs of irofulven.

McMorris TC, Chimmani R, Gurram M, Staake MD, Kelner MJ.

Bioorg Med Chem Lett. 2007 Dec 15;17(24):6770-2. Epub 2007 Oct 17.

PMID:
17977722
10.

Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia.

Roboz GJ, Giles FJ, Ritchie EK, Allen-Bard S, Curcio TJ, Wilkes MA, Park SL, Kantarjian HM, Faderl S, Ravandi F, Kelner MJ, Feldman EJ.

J Clin Oncol. 2007 Jan 1;25(1):10-5. Epub 2006 Dec 4.

PMID:
17146106
12.

Synthesis and biological activity of enantiomers of antitumor irofulven.

McMorris TC, Staake MD, Kelner MJ.

J Org Chem. 2004 Feb 6;69(3):619-23.

PMID:
14750783
13.

Structure-activity relationship studies of illudins: analogues possessing a spiro-cyclobutane ring.

McMorris TC, Cong Q, Kelner MJ.

J Org Chem. 2003 Dec 12;68(25):9648-53.

PMID:
14656090
14.

Basal expression of the human MAPEG members microsomal glutathione transferase 1 and prostaglandin E synthase genes is mediated by Sp1 and Sp3.

Ekström L, Lyrenäs L, Jakobsson PJ, Morgenstern R, Kelner MJ.

Biochim Biophys Acta. 2003 Jun 19;1627(2-3):79-84.

PMID:
12818425
15.

Reaction of irofulven with zinc and acid.

McMorris TC, Moon SS, Kelner MJ.

J Nat Prod. 2003 Feb;66(2):310-2.

PMID:
12608875
16.

Complementary and alternative groups contemplate the need for effectiveness, safety and cost-effectiveness research.

Kelner MJ, Boon H, Wellman B, Welsh S.

Complement Ther Med. 2002 Dec;10(4):235-9.

PMID:
12594975
17.

Anti-tumour compounds illudin S and Irofulven induce DNA lesions ignored by global repair and exclusively processed by transcription- and replication-coupled repair pathways.

Jaspers NG, Raams A, Kelner MJ, Ng JM, Yamashita YM, Takeda S, McMorris TC, Hoeijmakers JH.

DNA Repair (Amst). 2002 Dec 5;1(12):1027-38.

PMID:
12531012
18.

Sesquiterpenes from Omphalotus illudens.

McMorris TC, Kashinatham A, Lira R, Rundgren H, Gantzel PK, Kelner MJ, Dawe R.

Phytochemistry. 2002 Oct;61(4):395-8.

PMID:
12377232
19.

Enhanced antitumor activity of irofulven in combination with antimitotic agents.

Kelner MJ, McMorris TC, Rojas RJ, Trani NA, Velasco TR, Estes LA, Suthipinijtham P.

Invest New Drugs. 2002 Aug;20(3):271-9.

PMID:
12201490
20.

Enhanced antitumor activity of irofulven in combination with thiotepa or mitomycin C.

Kelner MJ, McMorris TC, Rojas RJ, Trani NA, Estes L.

Cancer Chemother Pharmacol. 2002 May;49(5):412-8. Epub 2002 Feb 12.

PMID:
11976836
21.

Structure-activity studies of antitumor agent irofulven (hydroxymethylacylfulvene) and analogues.

McMorris TC, Yu J, Lira R, Dawe R, MacDonald JR, Waters SJ, Estes LA, Kelner MJ.

J Org Chem. 2001 Sep 7;66(18):6158-63.

PMID:
11529745
22.

The effect of gamma hydroxybutyrate on serum osmolality.

Ingels M, Kelner MJ, Clark RF.

J Toxicol Clin Toxicol. 2001;39(4):417-8. No abstract available.

PMID:
11527239
23.

Sesquiterpenes from the basidiomycete Omphalotus illudens.

McMorris TC, Lira R, Gantzel PK, Kelner MJ, Dawe R.

J Nat Prod. 2000 Nov;63(11):1557-9.

PMID:
11087609
24.

Preparation and biological activity of amino acid and peptide conjugates of antitumor hydroxymethylacylfulvene.

McMorris TC, Yu J, Ngo HT, Wang H, Kelner MJ.

J Med Chem. 2000 Sep 21;43(19):3577-80.

PMID:
11000013
25.

Efficacy of MGI 114 (HMAF) against the MRP+ metastatic MV522 lung carcinoma xenograft.

Kelner MJ, McMorris TC, Estes LA, Oval MY, Rojas RJ, Lynn JR, Lanham KA, Samson KM.

Anticancer Drugs. 2000 Mar;11(3):217-24.

PMID:
10831281
29.

Anti-leukemic action of the novel agent MGI 114 (HMAF) and synergistic action with topotecan.

Kelner MJ, McMorris TC, Estes L, Samson KM, Trani NA, MacDonald JR.

Leukemia. 2000 Jan;14(1):136-41.

PMID:
10637489
30.

Metabolism of antitumor hydroxymethylacylfulvene by rat liver cytosol.

McMorris TC, Elayadi AN, Yu J, Hu Y, Kelner MJ.

Drug Metab Dispos. 1999 Sep;27(9):983-5.

PMID:
10460795
31.

Characterization of MGI 114 (HMAF) histiospecific toxicity in human tumor cell lines.

Kelner MJ, McMorris TC, Montoya MA, Estes L, Uglik SF, Rutherford M, Samson KM, Bagnell RD, Taetle R.

Cancer Chemother Pharmacol. 1999;44(3):235-40.

PMID:
10453725
32.

Distribution of microsomal glutathione transferase 1 in mammalian tissues. A predominant alternate first exon in human tissues.

Estonius M, Forsberg L, Danielsson O, Weinander R, Kelner MJ, Morgenstern R.

Eur J Biochem. 1999 Mar;260(2):409-13.

33.

Metabolism of antitumor acylfulvene by rat liver cytosol.

McMorris TC, Elayadi AN, Yu J, Kelner MJ.

Biochem Pharmacol. 1999 Jan 1;57(1):83-8.

PMID:
9920288
34.

Efficacy of MGI 114 (6-hydroxymethylacylfulvene, HMAF) against the mdr1/gp170 metastatic MV522 lung carcinoma xenograft.

Kelner MJ, McMorris TC, Estes L, Samson KM, Bagnell RD, Taetle R.

Eur J Cancer. 1998 May;34(6):908-13.

PMID:
9797706
36.

Characterization of acylfulvene histiospecific toxicity in human tumor cell lines.

Kelner MJ, McMorris TC, Montoya MA, Estes L, Uglik SF, Rutherford M, Samson KM, Bagnell RD, Taetle R.

Cancer Chemother Pharmacol. 1998;41(3):237-42.

PMID:
9443641
37.

Design and Synthesis of Antitumor Acylfulvenes.

McMorris TC, Yu J, Hu Y, Estes LA, Kelner MJ.

J Org Chem. 1997 May 2;62(9):3015-3018. No abstract available.

PMID:
11671671
38.

Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S.

MacDonald JR, Muscoplat CC, Dexter DL, Mangold GL, Chen SF, Kelner MJ, McMorris TC, Von Hoff DD.

Cancer Res. 1997 Jan 15;57(2):279-83.

39.

Heterologous expression of carbonyl reductase: demonstration of prostaglandin 9-ketoreductase activity and paraquat resistance.

Kelner MJ, Estes L, Rutherford M, Uglik SF, Peitzke JA.

Life Sci. 1997;61(23):2317-22.

PMID:
9408054
40.

Characterization of cellular accumulation and toxicity of illudin S in sensitive and nonsensitive tumor cells.

Kelner MJ, McMorris TC, Montoya MA, Estes L, Rutherford M, Samson KM, Taetle R.

Cancer Chemother Pharmacol. 1997;40(1):65-71.

PMID:
9137532
41.

Reactive oxygen species and their contribution to pathology in Down syndrome.

de Haan JB, Wolvetang EJ, Cristiano F, Iannello R, Bladier C, Kelner MJ, Kola I.

Adv Pharmacol. 1997;38:379-402. Review. No abstract available.

PMID:
8895817
42.

(Hydroxymethyl)acylfulvene: an illudin derivative with superior antitumor properties.

McMorris TC, Kelner MJ, Wang W, Yu J, Estes LA, Taetle R.

J Nat Prod. 1996 Sep;59(9):896-9.

PMID:
8864242
43.

Structural organization of the human microsomal glutathione S-transferase gene (GST12).

Kelner MJ, Stokely MN, Stovall NE, Montoya MA.

Genomics. 1996 Aug 15;36(1):100-3.

PMID:
8812420
45.
46.

Acylfulvenes, a new class of potent antitumor agents.

McMorris TC, Kelner MJ, Wang W, Diaz MA, Estes LA, Taetle R.

Experientia. 1996 Jan 16;52(1):75-80.

PMID:
8575564
47.

Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents.

Kelner MJ, McMorris TC, Estes L, Wang W, Samson KM, Taetle R.

Invest New Drugs. 1996;14(2):161-7.

PMID:
8913837
49.

Heterologous expression of selenium-dependent glutathione peroxidase affords cellular resistance to paraquat.

Kelner MJ, Bagnell RD, Uglik SF, Montoya MA, Mullenbach GT.

Arch Biochem Biophys. 1995 Oct 20;323(1):40-6.

PMID:
7487071

Supplemental Content

Loading ...
Support Center